세계의 소아용 의약품 및 백신 시장

Global Pediatric Drugs and Vaccines Market to Reach US$156.7 Billion by 2030

The global market for Pediatric Drugs and Vaccines estimated at US$104.7 Billion in the year 2023, is expected to reach US$156.7 Billion by 2030, growing at a CAGR of 5.9% over the analysis period 2023-2030. Conjugate Technology, one of the segments analyzed in the report, is expected to record a 7.1% CAGR and reach US$52.0 Billion by the end of the analysis period. Growth in the Live Attenuated Technology segment is estimated at 6.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$28.2 Billion While China is Forecast to Grow at 9.9% CAGR

The Pediatric Drugs and Vaccines market in the U.S. is estimated at US$28.2 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$35.4 Billion by the year 2030 trailing a CAGR of 9.9% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.0% and 6.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.3% CAGR.

Pediatric Drugs and Vaccines - Key Trends and Drivers

Pediatric drugs and vaccines represent a crucial segment in the pharmaceutical industry, dedicated to the health and wellbeing of children from infancy through adolescence. These medications and immunizations are specifically formulated to address the unique physiological needs of young patients, ensuring safety, efficacy, and appropriate dosing. Pediatric drugs cover a broad spectrum of therapeutic areas, including infectious diseases, chronic illnesses, nutritional deficiencies, and acute conditions. Vaccines play an equally vital role by providing immunity against a range of potentially life-threatening diseases such as measles, mumps, rubella, polio, and more. The development and approval process for pediatric drugs and vaccines involve rigorous clinical trials and regulatory scrutiny to ensure they meet stringent safety standards, given the vulnerable nature of the patient population.

Several trends and innovations are shaping the landscape of pediatric drugs and vaccines. One significant trend is the increasing emphasis on personalized medicine, which tailors treatments based on the genetic makeup of individual patients, thus improving therapeutic outcomes and minimizing adverse effects. Advances in biotechnology are leading to the development of novel vaccine platforms, such as mRNA vaccines, which have gained prominence during the COVID-19 pandemic. These platforms offer the potential for rapid development and high efficacy. Additionally, there is a growing focus on combination vaccines, which protect against multiple diseases with a single injection, thereby improving compliance and coverage rates. The integration of digital health technologies, including mobile health applications and telemedicine, is enhancing patient management and adherence to treatment regimens. Moreover, global health initiatives and partnerships are instrumental in increasing access to essential vaccines and medications in low- and middle-income countries.

The growth in the pediatric drugs and vaccines market is driven by several factors. Technological advancements in drug formulation and delivery systems are enabling the development of more effective and child-friendly medications, such as chewable tablets and dissolvable strips. The rising incidence of chronic diseases in children, including asthma, diabetes, and epilepsy, is fueling demand for long-term therapeutic solutions. Increasing awareness among parents and caregivers about the importance of timely vaccinations and preventive healthcare measures is leading to higher immunization rates. Additionally, government initiatives and funding for pediatric healthcare programs are providing a significant boost to market growth. The expanding scope of pediatric clinical trials, driven by regulatory incentives, is accelerating the introduction of new and innovative treatments. Lastly, the global focus on eradicating infectious diseases through vaccination campaigns is propelling the development and distribution of pediatric vaccines, ensuring better health outcomes for children worldwide.

Select Competitors (Total 76 Featured) -

• Abbott Laboratories
• Allergan Inc.
• Amgen Inc.
• AstraZeneca Plc
• Boehringer Ingelheim GmbH
• Bristol-Myers Squibb Company
• Eli Lilly and Company
• F. Hoffmann-La Roche Ltd
• Genentech Inc.
• GlaxoSmithKline Plc
• Janssen Biologics B.V
• Merck & Co. Inc.
• Novartis AG
• Novo Nordisk A/S
• Pfizer Inc.
• Sanofi
• Shionogi Inc.
• Shire Pharmaceuticals Group Plc

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • Global Economic Update
  • Pediatric Drugs and Vaccines - Global Key Competitors Percentage Market Share in 2024 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Increasing Incidence of Chronic Pediatric Diseases Throws the Spotlight on Long-Term Therapeutic Solutions
  • Advancements in Drug Formulation Propel Growth in Pediatric Medications Market
  • Rising Awareness about Preventive Healthcare Expands Addressable Market Opportunity for Pediatric Vaccines
  • Innovations in Vaccine Platforms Strengthen Business Case for Next-Generation Immunizations
  • Government Initiatives and Funding Generates Demand for Pediatric Healthcare Programs
  • Integration of Digital Health Technologies Drives Adoption of Advanced Patient Management Tools
  • Combination Vaccines Accelerate Demand by Improving Compliance and Coverage Rates
  • Global Health Initiatives Ensure Increasing Access to Essential Pediatric Vaccines
  • Personalized Medicine Enhances Therapeutic Outcomes for Pediatric Patients
  • Advances in Drug Delivery Systems Sustain Growth in Pediatric Drug Administration
  • Expansion of Telemedicine Services Drives Adoption of Remote Pediatric Care Solutions
  • Rising Investment in Biotechnology Generates Opportunities for Novel Pediatric Treatments
  • Increasing Focus on Eradicating Infectious Diseases Propels Growth in Pediatric Vaccination Programs
  • Enhanced Safety and Efficacy Standards Generate Confidence in Pediatric Drug and Vaccine Adoption
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Pediatric Drugs and Vaccines Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Pediatric Drugs and Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 4: World 16-Year Perspective for Pediatric Drugs and Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Conjugate by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Conjugate by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 7: World 16-Year Perspective for Conjugate by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Live Attenuated by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Live Attenuated by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 10: World 16-Year Perspective for Live Attenuated by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Inactivated by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Inactivated by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 13: World 16-Year Perspective for Inactivated by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Subunit by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Subunit by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 16: World 16-Year Perspective for Subunit by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Toxoid by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Toxoid by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 19: World 16-Year Perspective for Toxoid by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 22: World 16-Year Perspective for Other Technologies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 25: World 16-Year Perspective for Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 28: World 16-Year Perspective for Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Pediatric Drugs and Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
  • TABLE 29: USA Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 30: USA Historic Review for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 31: USA 16-Year Perspective for Pediatric Drugs and Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies for the Years 2014, 2024 & 2030
  • TABLE 32: USA Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 33: USA Historic Review for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 34: USA 16-Year Perspective for Pediatric Drugs and Vaccines by Product Type - Percentage Breakdown of Value Sales for Vaccines and Drugs for the Years 2014, 2024 & 2030
• CANADA
  • TABLE 35: Canada Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 36: Canada Historic Review for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 37: Canada 16-Year Perspective for Pediatric Drugs and Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies for the Years 2014, 2024 & 2030
  • TABLE 38: Canada Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 39: Canada Historic Review for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 40: Canada 16-Year Perspective for Pediatric Drugs and Vaccines by Product Type - Percentage Breakdown of Value Sales for Vaccines and Drugs for the Years 2014, 2024 & 2030
• JAPAN
  • Pediatric Drugs and Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
  • TABLE 41: Japan Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 42: Japan Historic Review for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 43: Japan 16-Year Perspective for Pediatric Drugs and Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies for the Years 2014, 2024 & 2030
  • TABLE 44: Japan Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 45: Japan Historic Review for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 46: Japan 16-Year Perspective for Pediatric Drugs and Vaccines by Product Type - Percentage Breakdown of Value Sales for Vaccines and Drugs for the Years 2014, 2024 & 2030
• CHINA
  • Pediatric Drugs and Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
  • TABLE 47: China Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 48: China Historic Review for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 49: China 16-Year Perspective for Pediatric Drugs and Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies for the Years 2014, 2024 & 2030
  • TABLE 50: China Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 51: China Historic Review for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 52: China 16-Year Perspective for Pediatric Drugs and Vaccines by Product Type - Percentage Breakdown of Value Sales for Vaccines and Drugs for the Years 2014, 2024 & 2030
• EUROPE
  • Pediatric Drugs and Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
  • TABLE 53: Europe Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 54: Europe Historic Review for Pediatric Drugs and Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 55: Europe 16-Year Perspective for Pediatric Drugs and Vaccines by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
  • TABLE 56: Europe Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 57: Europe Historic Review for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 58: Europe 16-Year Perspective for Pediatric Drugs and Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies for the Years 2014, 2024 & 2030
  • TABLE 59: Europe Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 60: Europe Historic Review for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 61: Europe 16-Year Perspective for Pediatric Drugs and Vaccines by Product Type - Percentage Breakdown of Value Sales for Vaccines and Drugs for the Years 2014, 2024 & 2030
• FRANCE
  • Pediatric Drugs and Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
  • TABLE 62: France Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 63: France Historic Review for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 64: France 16-Year Perspective for Pediatric Drugs and Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies for the Years 2014, 2024 & 2030
  • TABLE 65: France Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 66: France Historic Review for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 67: France 16-Year Perspective for Pediatric Drugs and Vaccines by Product Type - Percentage Breakdown of Value Sales for Vaccines and Drugs for the Years 2014, 2024 & 2030
• GERMANY
  • Pediatric Drugs and Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
  • TABLE 68: Germany Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 69: Germany Historic Review for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 70: Germany 16-Year Perspective for Pediatric Drugs and Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies for the Years 2014, 2024 & 2030
  • TABLE 71: Germany Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 72: Germany Historic Review for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 73: Germany 16-Year Perspective for Pediatric Drugs and Vaccines by Product Type - Percentage Breakdown of Value Sales for Vaccines and Drugs for the Years 2014, 2024 & 2030
• ITALY
  • TABLE 74: Italy Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 75: Italy Historic Review for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 76: Italy 16-Year Perspective for Pediatric Drugs and Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies for the Years 2014, 2024 & 2030
  • TABLE 77: Italy Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 78: Italy Historic Review for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 79: Italy 16-Year Perspective for Pediatric Drugs and Vaccines by Product Type - Percentage Breakdown of Value Sales for Vaccines and Drugs for the Years 2014, 2024 & 2030
• UNITED KINGDOM
  • Pediatric Drugs and Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
  • TABLE 80: UK Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 81: UK Historic Review for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 82: UK 16-Year Perspective for Pediatric Drugs and Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies for the Years 2014, 2024 & 2030
  • TABLE 83: UK Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 84: UK Historic Review for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 85: UK 16-Year Perspective for Pediatric Drugs and Vaccines by Product Type - Percentage Breakdown of Value Sales for Vaccines and Drugs for the Years 2014, 2024 & 2030
• SPAIN
  • TABLE 86: Spain Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 87: Spain Historic Review for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 88: Spain 16-Year Perspective for Pediatric Drugs and Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies for the Years 2014, 2024 & 2030
  • TABLE 89: Spain Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 90: Spain Historic Review for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 91: Spain 16-Year Perspective for Pediatric Drugs and Vaccines by Product Type - Percentage Breakdown of Value Sales for Vaccines and Drugs for the Years 2014, 2024 & 2030
• RUSSIA
  • TABLE 92: Russia Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 93: Russia Historic Review for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 94: Russia 16-Year Perspective for Pediatric Drugs and Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies for the Years 2014, 2024 & 2030
  • TABLE 95: Russia Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 96: Russia Historic Review for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 97: Russia 16-Year Perspective for Pediatric Drugs and Vaccines by Product Type - Percentage Breakdown of Value Sales for Vaccines and Drugs for the Years 2014, 2024 & 2030
• REST OF EUROPE
  • TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 99: Rest of Europe Historic Review for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 100: Rest of Europe 16-Year Perspective for Pediatric Drugs and Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies for the Years 2014, 2024 & 2030
  • TABLE 101: Rest of Europe Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 102: Rest of Europe Historic Review for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 103: Rest of Europe 16-Year Perspective for Pediatric Drugs and Vaccines by Product Type - Percentage Breakdown of Value Sales for Vaccines and Drugs for the Years 2014, 2024 & 2030
• ASIA-PACIFIC
  • Pediatric Drugs and Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
  • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 105: Asia-Pacific Historic Review for Pediatric Drugs and Vaccines by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 106: Asia-Pacific 16-Year Perspective for Pediatric Drugs and Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
  • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 108: Asia-Pacific Historic Review for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 109: Asia-Pacific 16-Year Perspective for Pediatric Drugs and Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies for the Years 2014, 2024 & 2030
  • TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 111: Asia-Pacific Historic Review for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 112: Asia-Pacific 16-Year Perspective for Pediatric Drugs and Vaccines by Product Type - Percentage Breakdown of Value Sales for Vaccines and Drugs for the Years 2014, 2024 & 2030
• AUSTRALIA
  • Pediatric Drugs and Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
  • TABLE 113: Australia Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 114: Australia Historic Review for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 115: Australia 16-Year Perspective for Pediatric Drugs and Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies for the Years 2014, 2024 & 2030
  • TABLE 116: Australia Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 117: Australia Historic Review for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 118: Australia 16-Year Perspective for Pediatric Drugs and Vaccines by Product Type - Percentage Breakdown of Value Sales for Vaccines and Drugs for the Years 2014, 2024 & 2030
• INDIA
  • Pediatric Drugs and Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
  • TABLE 119: India Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 120: India Historic Review for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 121: India 16-Year Perspective for Pediatric Drugs and Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies for the Years 2014, 2024 & 2030
  • TABLE 122: India Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 123: India Historic Review for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 124: India 16-Year Perspective for Pediatric Drugs and Vaccines by Product Type - Percentage Breakdown of Value Sales for Vaccines and Drugs for the Years 2014, 2024 & 2030
• SOUTH KOREA
  • TABLE 125: South Korea Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 126: South Korea Historic Review for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 127: South Korea 16-Year Perspective for Pediatric Drugs and Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies for the Years 2014, 2024 & 2030
  • TABLE 128: South Korea Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 129: South Korea Historic Review for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 130: South Korea 16-Year Perspective for Pediatric Drugs and Vaccines by Product Type - Percentage Breakdown of Value Sales for Vaccines and Drugs for the Years 2014, 2024 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 132: Rest of Asia-Pacific Historic Review for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 133: Rest of Asia-Pacific 16-Year Perspective for Pediatric Drugs and Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies for the Years 2014, 2024 & 2030
  • TABLE 134: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 135: Rest of Asia-Pacific Historic Review for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 136: Rest of Asia-Pacific 16-Year Perspective for Pediatric Drugs and Vaccines by Product Type - Percentage Breakdown of Value Sales for Vaccines and Drugs for the Years 2014, 2024 & 2030
• LATIN AMERICA
  • Pediatric Drugs and Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
  • TABLE 137: Latin America Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 138: Latin America Historic Review for Pediatric Drugs and Vaccines by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 139: Latin America 16-Year Perspective for Pediatric Drugs and Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
  • TABLE 140: Latin America Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 141: Latin America Historic Review for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 142: Latin America 16-Year Perspective for Pediatric Drugs and Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies for the Years 2014, 2024 & 2030
  • TABLE 143: Latin America Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 144: Latin America Historic Review for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 145: Latin America 16-Year Perspective for Pediatric Drugs and Vaccines by Product Type - Percentage Breakdown of Value Sales for Vaccines and Drugs for the Years 2014, 2024 & 2030
• ARGENTINA
  • TABLE 146: Argentina Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 147: Argentina Historic Review for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 148: Argentina 16-Year Perspective for Pediatric Drugs and Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies for the Years 2014, 2024 & 2030
  • TABLE 149: Argentina Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 150: Argentina Historic Review for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 151: Argentina 16-Year Perspective for Pediatric Drugs and Vaccines by Product Type - Percentage Breakdown of Value Sales for Vaccines and Drugs for the Years 2014, 2024 & 2030
• BRAZIL
  • TABLE 152: Brazil Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 153: Brazil Historic Review for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 154: Brazil 16-Year Perspective for Pediatric Drugs and Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies for the Years 2014, 2024 & 2030
  • TABLE 155: Brazil Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 156: Brazil Historic Review for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 157: Brazil 16-Year Perspective for Pediatric Drugs and Vaccines by Product Type - Percentage Breakdown of Value Sales for Vaccines and Drugs for the Years 2014, 2024 & 2030
• MEXICO
  • TABLE 158: Mexico Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 159: Mexico Historic Review for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 160: Mexico 16-Year Perspective for Pediatric Drugs and Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies for the Years 2014, 2024 & 2030
  • TABLE 161: Mexico Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 162: Mexico Historic Review for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 163: Mexico 16-Year Perspective for Pediatric Drugs and Vaccines by Product Type - Percentage Breakdown of Value Sales for Vaccines and Drugs for the Years 2014, 2024 & 2030
• REST OF LATIN AMERICA
  • TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 165: Rest of Latin America Historic Review for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 166: Rest of Latin America 16-Year Perspective for Pediatric Drugs and Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies for the Years 2014, 2024 & 2030
  • TABLE 167: Rest of Latin America Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 168: Rest of Latin America Historic Review for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 169: Rest of Latin America 16-Year Perspective for Pediatric Drugs and Vaccines by Product Type - Percentage Breakdown of Value Sales for Vaccines and Drugs for the Years 2014, 2024 & 2030
• MIDDLE EAST
  • Pediatric Drugs and Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
  • TABLE 170: Middle East Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 171: Middle East Historic Review for Pediatric Drugs and Vaccines by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 172: Middle East 16-Year Perspective for Pediatric Drugs and Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
  • TABLE 173: Middle East Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 174: Middle East Historic Review for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 175: Middle East 16-Year Perspective for Pediatric Drugs and Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies for the Years 2014, 2024 & 2030
  • TABLE 176: Middle East Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 177: Middle East Historic Review for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 178: Middle East 16-Year Perspective for Pediatric Drugs and Vaccines by Product Type - Percentage Breakdown of Value Sales for Vaccines and Drugs for the Years 2014, 2024 & 2030
• IRAN
  • TABLE 179: Iran Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 180: Iran Historic Review for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 181: Iran 16-Year Perspective for Pediatric Drugs and Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies for the Years 2014, 2024 & 2030
  • TABLE 182: Iran Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 183: Iran Historic Review for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 184: Iran 16-Year Perspective for Pediatric Drugs and Vaccines by Product Type - Percentage Breakdown of Value Sales for Vaccines and Drugs for the Years 2014, 2024 & 2030
• ISRAEL
  • TABLE 185: Israel Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 186: Israel Historic Review for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 187: Israel 16-Year Perspective for Pediatric Drugs and Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies for the Years 2014, 2024 & 2030
  • TABLE 188: Israel Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 189: Israel Historic Review for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 190: Israel 16-Year Perspective for Pediatric Drugs and Vaccines by Product Type - Percentage Breakdown of Value Sales for Vaccines and Drugs for the Years 2014, 2024 & 2030
• SAUDI ARABIA
  • TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 192: Saudi Arabia Historic Review for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 193: Saudi Arabia 16-Year Perspective for Pediatric Drugs and Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies for the Years 2014, 2024 & 2030
  • TABLE 194: Saudi Arabia Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 195: Saudi Arabia Historic Review for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 196: Saudi Arabia 16-Year Perspective for Pediatric Drugs and Vaccines by Product Type - Percentage Breakdown of Value Sales for Vaccines and Drugs for the Years 2014, 2024 & 2030
• UNITED ARAB EMIRATES
  • TABLE 197: UAE Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 198: UAE Historic Review for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 199: UAE 16-Year Perspective for Pediatric Drugs and Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies for the Years 2014, 2024 & 2030
  • TABLE 200: UAE Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 201: UAE Historic Review for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 202: UAE 16-Year Perspective for Pediatric Drugs and Vaccines by Product Type - Percentage Breakdown of Value Sales for Vaccines and Drugs for the Years 2014, 2024 & 2030
• REST OF MIDDLE EAST
  • TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 204: Rest of Middle East Historic Review for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 205: Rest of Middle East 16-Year Perspective for Pediatric Drugs and Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies for the Years 2014, 2024 & 2030
  • TABLE 206: Rest of Middle East Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 207: Rest of Middle East Historic Review for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 208: Rest of Middle East 16-Year Perspective for Pediatric Drugs and Vaccines by Product Type - Percentage Breakdown of Value Sales for Vaccines and Drugs for the Years 2014, 2024 & 2030
• AFRICA
  • Pediatric Drugs and Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
  • TABLE 209: Africa Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 210: Africa Historic Review for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 211: Africa 16-Year Perspective for Pediatric Drugs and Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies for the Years 2014, 2024 & 2030
  • TABLE 212: Africa Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 213: Africa Historic Review for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 214: Africa 16-Year Perspective for Pediatric Drugs and Vaccines by Product Type - Percentage Breakdown of Value Sales for Vaccines and Drugs for the Years 2014, 2024 & 2030

IV. COMPETITION